These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34963683)

  • 1. Potential of [
    Puuvuori E; Rokka J; Carlsson PO; Li Z; Eriksson J; Eriksson O
    Sci Rep; 2021 Dec; 11(1):24466. PubMed ID: 34963683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
    Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
    J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
    Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
    J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical PET Studies of [
    Thomsen MB; Schacht AC; Alstrup AKO; Jacobsen J; Lillethorup TP; Bærentzen SL; Noer O; Orlowski D; Elfving B; Müller HK; Brooks DJ; Landau AM
    Mol Imaging Biol; 2020 Oct; 22(5):1290-1300. PubMed ID: 32514885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain.
    Warnock GI; Aerts J; Bahri MA; Bretin F; Lemaire C; Giacomelli F; Mievis F; Mestdagh N; Buchanan T; Valade A; Mercier J; Wood M; Gillard M; Seret A; Luxen A; Salmon E; Plenevaux A
    J Nucl Med; 2014 Aug; 55(8):1336-41. PubMed ID: 24935992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation and noninvasive kinetic modeling of [
    Bertoglio D; Verhaeghe J; Miranda A; Kertesz I; Cybulska K; Korat Š; Wyffels L; Stroobants S; Mrzljak L; Dominguez C; Liu L; Skinbjerg M; Munoz-Sanjuan I; Staelens S
    J Cereb Blood Flow Metab; 2020 Jun; 40(6):1351-1362. PubMed ID: 31307287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
    Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J
    Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of cerebral drug occupancy in humans using a single PET-scan: A [
    Marstrand-Joergensen MR; Laurell GL; Herrmann S; Nasser A; Johansen A; Lund A; Andersen TL; Knudsen GM; Pinborg LH
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3292-3304. PubMed ID: 38758370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo imaging of synaptic density with [
    Xiong M; Roshanbin S; Rokka J; Schlein E; Ingelsson M; Sehlin D; Eriksson J; Syvänen S
    Neuroimage; 2021 Oct; 239():118302. PubMed ID: 34174391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
    Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
    Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
    Bertoglio D; Verhaeghe J; Wyffels L; Miranda A; Stroobants S; Mrzljak L; Dominguez C; Skinbjerg M; Bard J; Liu L; Munoz-Sanjuan I; Staelens S
    J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and in vivo evaluation of [
    Li S; Cai Z; Zhang W; Holden D; Lin SF; Finnema SJ; Shirali A; Ropchan J; Carre S; Mercier J; Carson RE; Nabulsi N; Huang Y
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1952-1965. PubMed ID: 31175396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SV2A PET Imaging Is a Noninvasive Marker for the Detection of Spinal Damage in Experimental Models of Spinal Cord Injury.
    Bertoglio D; Halloin N; Lombaerde S; Jankovski A; Verhaeghe J; Nicaise C; Staelens S
    J Nucl Med; 2022 Aug; 63(8):1245-1251. PubMed ID: 35027368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non-human primate and human brain.
    Varnäs K; Stepanov V; Halldin C
    Synapse; 2020 Oct; 74(10):e22157. PubMed ID: 32259300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic evaluation and test-retest reproducibility of [
    Finnema SJ; Nabulsi NB; Mercier J; Lin SF; Chen MK; Matuskey D; Gallezot JD; Henry S; Hannestad J; Huang Y; Carson RE
    J Cereb Blood Flow Metab; 2018 Nov; 38(11):2041-2052. PubMed ID: 28792356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying SV2A density and drug occupancy in the human brain using [
    Koole M; van Aalst J; Devrome M; Mertens N; Serdons K; Lacroix B; Mercier J; Sciberras D; Maguire P; Van Laere K
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):396-406. PubMed ID: 30121895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the In Vivo Specificity of [
    Serrano ME; Becker G; Bahri MA; Seret A; Mestdagh N; Mercier J; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Molecules; 2019 May; 24(9):. PubMed ID: 31052478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics and 28-day test-retest repeatability and reproducibility of [
    Tuncel H; Boellaard R; Coomans EM; de Vries EF; Glaudemans AW; Feltes PK; García DV; Verfaillie SC; Wolters EE; Sweeney SP; Ryan JM; Ivarsson M; Lynch BA; Schober P; Scheltens P; Schuit RC; Windhorst AD; De Deyn PP; van Berckel BN; Golla SS
    J Cereb Blood Flow Metab; 2021 Jun; 41(6):1338-1350. PubMed ID: 34013797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.